Patent 8026097 was granted and assigned to St. Jude Children's Research Hospital on September, 2011 by the United States Patent and Trademark Office.
The present invention relates to novel methods for preferentially activating and expanding NK cells. The methods utilize the stimulatory effects of IL-15 and CD137 ligand to preferentially expand and activate NK cells in a mixed cell culture comprising NK cells.